Bacterial counts from five over-the-counter probiotics: Are you getting what you paid for?

Anaerobe

Volumn 25, Issue , 2014, Pages 1-4

  Goldstein, Ellie J C ^a,b   Citron, Diane M ^a   Claros, Marina C ^a   Tyrrell, Kerin L ^a  

^a R M ALDEN RESEARCH LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clostridium difficile; Lactobacillus; Probiotics; Saccharomyces

Indexed keywords

ALIGN; BIO K; CULTURELLE; FLORASTOR; LACTINEX; PROBIOTIC AGENT; UNCLASSIFIED DRUG; NON PRESCRIPTION DRUG;

ARTICLE; BACTERIAL COUNT; BACTERIAL VIABILITY; BIFIDOBACTERIUM LONGUM INFANTIS; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG PACKAGING; DRUG SYNTHESIS; INCUBATION TIME; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS HELVETICUS; LACTOBACILLUS RHAMNOSUS; PRIORITY JOURNAL; SACCHAROMYCES BOULARDII; BACTERIA; BACTERIAL LOAD; ISOLATION AND PURIFICATION; MICROBIAL VIABILITY;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM LONGUM BV. INFANTIS; CLOSTRIDIUM DIFFICILE; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS HELVETICUS; LACTOBACILLUS RHAMNOSUS; SACCHAROMYCES; SACCHAROMYCES BOULARDII;

BACTERIA; BACTERIAL LOAD; COLONY COUNT, MICROBIAL; MICROBIAL VIABILITY; NONPRESCRIPTION DRUGS; PROBIOTICS;

EID: 84887568245     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2013.10.005     Document Type: Article

References (19)

1. Owens R.C., Donskey C.J., Gaynes R.P., Loo V.G., Muto C.A. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl.1):S19-S31.
2. Hempel S., Newberry S.J., Maher A.R., Wang Z., Miles J.N., Shanman R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAm Med Assoc 2012, 307:1959-1969.
3. Jarvis W.R., Schlosser J., Jarvis A.A., Chinn R.Y. National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am J Infect Control 2009, 37:263-270.
4. Mullane K.M., Miller M.A., Weiss K., Lentnek A., Golan Y., Sears P.S., et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011, 53:440-447.
5. Petrella L.A., Sambol S.P., Cheknis A., Nagaro K., Kean Y., Sears P.S., et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C.difficile BI strain. Clin Infect Dis 2012, 55(3):351-357.
6. Venuto C., Butler M., Ashley E.D., Brown J. Alternative therapies for Clostridium difficile infections. Pharmacotherapy 2010, 30:1266-1278.
7. Bakken J.S., Borody T., Brandt L.J., Brill J.V., Demarco D.C., Franzos M.A., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011, 9:1044-1049.
8. Araya M, Morelli L, Reid G, Sanders ME, Stanton C, Pineiro M etal. Guidelines for the Evaluation of Probiotics in Food. Joint FAO/WHO Working Group Meeting, 30 April-1 May 2002; London Ontario, Canada. http://www.who.int/foodsafety/publications/fs_management/probiotics2/en/.
9. Azais-Braesco V., Bresson J.L., Guarner F., Corthier G. Not all lactic acid bacteria are probiotics,. . .but some are. Br J Nutr 2010, 103:1079-1081.
10. Grzeskowiak L., Isolauri E., Salminen S., Gueimonde M. Manufacturing process influences properties of probiotic bacteria. Br J Nutr 2011, 105:887-894.
11. McFarland L.V. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 2009, 15:274-280.
12. Videlock E.J., Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2012, 35:1355-1369.
13. Johnson S., Maziade P.J., McFarland L.V., Trick W., Donskey C., Currie B., et al. Is primary prevention of Clostridium difficile infection possible with tsapecific probiotics. Int J Antimcrob Agents 2012, 16. e786-92.
14. Elmer G.W., McFarland L.V., Surawicz C.M., Danko L., Greenberg R.N. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 1999, 13:1663-1668.
15. Gao X.W., Mubasher M., Fang C.Y., Reifer C., Miller L.E. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010, 105:1636-1641.
16. Elliot E., Teversham K. An evaluation of nine probiotics available in South Africa, August 2003. SAfr Med J 2004, 94:121-124.
17. Drisko J., Bischoff B., Giles C., Adelson M., Rao R.V., McCallum R. Evaluation of five probiotic products for label claims by DNA extraction and polymerase chain reaction analysis. Dig Dis Sci 2005, 50:1113-1117.
18. Marcobal A., Underwood M.A., Mills D.A. Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis. JPediatr Gastroenterol Nutr 2008, 46:608-611.
19. Weese J.S., Martin H. Assessment of commercial probiotic bacterial contents and label accuracy. Can Vet J 2011, 52:43-46.